Ascendis Pharma A (ASND) Investment Gain (Loss) (2020 - 2024)

Ascendis Pharma A has reported Investment Gain (Loss) for 5 years, with the latest figure at -$1068.6 in Q4 2024.

• Quarterly Investment Gain (Loss) fell 100.02% year-over-year to -$1068.6 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$1068.6 (down 100.01% YoY) and the FY2024 annual result came in at $7.9 million, down 97.49% from the prior year.
• Investment Gain (Loss) eased to -$1068.6 in Q4 2024 per ASND's latest filing, from $8.0 million in the prior quarter.
• Over five years, Investment Gain (Loss) peaked at $227.3 million in Q1 2023 and troughed at -$1068.6 in Q4 2024.
• A 5-year average of $63.2 million and a median of $51.6 million in 2023 frame the typical range for Investment Gain (Loss).
• The sharpest annual moves came in 2023 and 2024: Investment Gain (Loss) jumped 212.11% in 2023, then plunged 100.02% in 2024.
• Over 5 years, Investment Gain (Loss) stood at $155.5 million in 2020, then slumped by 76.92% to $35.9 million in 2021, then surged by 59.18% to $57.1 million in 2022, then sank by 87.6% to $7.1 million in 2023, then plunged by 100.02% to -$1068.6 in 2024.
• According to Business Quant data, Investment Gain (Loss) over the past three periods registered -$1068.6, $8.0 million, and $7.1 million for Q4 2024, Q1 2024, and Q4 2023 respectively.